Skip to content

Ionis Pharmaceuticals IONS Effect of cross-border tax laws

Effect of cross-border tax laws at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$7.45M

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount.

The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's effect of cross-border tax laws.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's effect of cross-border tax laws?
Ionis Pharmaceuticals (IONS) reported effect of cross-border tax laws of $114.75K in Q4 2025.
What does effect of cross-border tax laws mean?
The tax impact resulting from cross-border financial and operational activities.
How do you interpret effect of cross-border tax laws?
Higher costs indicate increased tax friction or regulatory challenges in international operations.
How does effect of cross-border tax laws compare across companies?
Disclosed by companies with significant cross-border intercompany transactions.